AJ Barbarito, Esq, explains how ERISA and Medicare Part D preemption limit state PBM laws and why a private right of action may be the most effective path forward.
News|Articles|October 15, 2024
Optimizing Heart Failure Outcomes With Medication Management, Screening | ACCP 2024
Author(s)Lauren Biscaldi, MS
Pharmacists can screen for social determinants of health and patient beliefs about medications as a way to improve adherence and subsequent outcomes in heart failure.
Advertisement
Pharmacists can play a key role in heart failure treatment. Three studies presented at the American College of Clinical Pharmacy 2024 Annual Meeting looked at medication satisfaction, management, and social determinants of health screening.
References
Barry A, Boswell R, Dhanoa T. Patients’ beliefs about their heart failure medications. Presented at: American College of Clinical Pharmacy 2024 Annual Meeting; October 12-15, 2024; Phoenix, AZ. Poster TUES-25.
Sigler M, Alvarez C, Parker R, Perkins A. Effectiveness of SGLT2i in veterans with heart failure and type 2 diabetes mellitus recently hospitalized for acute decompensated heart failure. Presented at: American College of Clinical Pharmacy 2024 Annual Meeting; October 12-15, 2024; Phoenix, AZ. Poster MON-17.
Guerrero J, Blodgett A, Muvuka B. Pharmacist role in examining social determinants of health and heart failure readmissions within the hospital readmission reduction program. Presented at: American College of Clinical Pharmacy 2024 Annual Meeting; October 12-15, 2024; Phoenix, AZ. Poster TUES-54.
Advertisement
Related to this article
Harini Bupathi, Esq, joins to discuss the impacts of PBM network terminations and how pharmacies can recover financially.
AJ Barbarito, Esq, provides nuance to the evolving pharmacy reimbursement landscape and how PBMs and pharmacies alike are adapting as they approach 2027.
Nicole Pezzino, PharmD, BCACP, BC-ADM, CDCES, details how pharmacies can utilize the booming GLP-1 medication class for greater revenue opportunities.
Matt Martin, PharmD, BCSCP, explores current developments in the peptide space and what pharmacists need to know amid FDA decision-making processes.
Sara Hover, RPh, FAARM, explains how these products are putting pharmacists at the center of safety and evidence evaluations one patient at a time.
Lara Zakaria, PharmD, MS, CNS, FMCP, discusses her perspectives regarding the emergence of wearable technology among community pharmacy patients.
In celebration of the organization’s recent convention, NCPA released its annual digest report for members, providing a detailed overview of independent community pharmacy.
Advertisement
Advertisement
Trending on Drug Topics
1
PBM Underpayment Persists as Cost-Plus Brings New Strain | NCPA 2026
2
Pharmacist Roles, Risks in Guiding AI-Enabled Medical Device Use
3
Q&A: Why Enforcement Is the Weak Link in State PBM Reform | NCPA 2026
4
Vaccine Fatigue May Stall Patient Uptake More Than Hesitancy
5